Amsbio, Abingdon, UK, has launched a range of ready-to-use SARS-CoV-2 spike protein-coupled magnetic beads that combine convenience, minimum nonspecific binding, and developed operational protocols.
Developed for immunocapture, cell stimulating, biopanning, and flow cytometry applications the new products use biotinylated SARS-CoV-2 spike protein precoupled to streptavidin conjugated magnetic beads, which can capture the anti-SARS-CoV-2 antibody or ACE2 protein from cell or serum sample. Because streptavidin has a high affinity for biotin with a dissociation constant (Kd) on the order of 10 to 14 mol/L, the biotinylated protein can bind to the magnetic beads irreversibly.
The complex may be removed from the solution manually using a magnetic separator. The bound SARS-CoV-2 spike proteins can then be dissociated from the magnetic beads using an elution buffer. All magnetic bead products from Amsbio are of uniform size, narrow size distribution with large surface area and unique surface coating.
Amsbio has also introduced SARS-CoV-2 spike S1 protein-coated and SARS-CoV2 spike protein RBD-Coated microplates optimized for enzyme-linked immunosorbent assay (ELISA) and biopanning. These assay kits employ a standard indirect-ELISA format which provide a rapid quantification of anti-SARS-CoV-2 antibodies or ACE-2 protein in serum by binding to spike protein S1.
For more information, visit Amsbio.
